Table 3 Proportional hazards analysis of the impact of adalimumab versus disease-modifying antirheumatic drug therapy on American College of Rheumatology (ACR) response, European League Against Rheumatism (EULAR) good response and 28-joint Disease Activity Score (DAS28) remission*
OutcomeHazard ratio among DE033 patients (95% CI)
Achieve ACR201.890 (1.477 to 2.419)
Achieve ACR501.949 (1.353 to 2.806)
Achieve ACR702.088 (1.137 to 3.836)
Achieve EULAR good response1.625 (1.188 to 2.224)
Achieve disease remission—all patients1.826 (1.323 to 2.520)
Achieve disease remission—patients without remission at study enrolment2.511 (1.721 to 3.662)
  • *From proportional hazards regressions controlling for time to event (ACR response or disease remission), duration of study enrolment, percentage working at baseline (for analysis of all patients only) and baseline age, erythrocyte sedimentation rate, C-reactive protein concentration, number of swollen and tender joints, DAS28, and joint pain, patient-rated global and physician-rated global assessment visual analogue scale scores.